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BACKGROUND: Pregnane X receptor (PXR) is a nuclear receptor that regulates the metabolism and disposition of various xenobiotics
and endobioitics. We investigated a novel PXR function in regulating colon tumourigenesis in this study.
METHODS: Histochemistry, transfection, cell proliferation assay, anchorage-a-dependent assay, xenograft, immunohistochemistry,
immunofluorescence flow cytometry.
RESULTS: Using histochemistry analysis, we found that PXR expressions were lost or greatly diminished in many colon tumours. Ectopic
expression of human PXR through stable transfection of PXR into colon cancer cell line HT29 significantly inhibited cell proliferation
as determined by cell proliferation assay and anchorage-independent assay. Pregnane X receptor suppressed significantly HT29
xenograft tumour growth in nude mice compared with control (310±6.2 vs 120±6mg, Po0.01). Immunohistochemistry and
immunofluorescence analysis of Ki-67 on excised xenograft tumour tissues showed that PXR inhibited cancer cell proliferation.
Furthermore, expressions of PXR and Ki-67 were mutually exclusive. The flow cytometry analysis indicated that PXR caused G0/G1
cell-cycle arrest. p21
WAF1/CIP1 expression was markedly elevated whereas E2F1 expression was inhibited by PXR.
CONCLUSION: PXR inhibits the proliferation and tumourigenicity of colon cancer cells by controlling cell cycle at G0/G1 cell phase
by regulating p21
WAF1/CIP1 and E2F/Rb pathways.
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Pregnane X receptor (PXR), which is also known as the steroid
and xenobiotic receptor, was identified as a nuclear receptor
that regulates the metabolism and disposition of various
xenobiotics and endobiotics (Bertilsson et al, 1998; Blumberg
et al, 1998; Lehmann et al, 1998). PXR is a ligand-dependent
transcription factor with agonists and antagonists encompassing
wide range of structurally diverse endogenous and exogenous
compounds. The PXR ligands include more than 50% of clinical
drugs/therapeutics, various environmental contaminants such as
polyhalogenated and polycyclic aromatic hydrocarbons as well as
endogenous substances such as secondary bile acids and steroids.
The xenosensor and effector functions of PXR are carried out
through coordinately regulating phase I, II and III detoxifying
enzymes and membrane-bound transporters (Handschin and
Meyer, 2003).
Interestingly, recent results from several laboratories indicate
that physiological functions of PXR are not limited to regulation
of xenobiotic metabolism. Novel physiological functions of PXR
have been discovered including regulation of NF-kB-mediated
inflammatory pathway, vitamin D metabolism, cholesterol and
lipid homoeostasis, energy homoeostasis, apoptosis as well as cell
proliferation (reviewed in Zhou et al, 2009). These new results
suggest multitudes of PXR functions and potential use of PXR
as a therapeutic target for treating certain diseases such as
inflammatory bowl disease (IBD), cholestasis and hyperlipidemia
in which PXR may influence the disease development.
It is especially noteworthy that several aspects of novel
physiological functions of PXR are critical for carcinogenesis and
cancer therapy. For example, our recent results suggest that PXR is
important in preventing carcinogen-induced DNA damages
(Naspinski et al, 2008). We and others have found cross talk
between PXR-regulated pathway and NF-kB-regulated pathways
(Gu et al, 2006; Zhou et al, 2006). These interactions create a
‘checks and balances’ relationship between pathways, which may
have a role in some pathological processes such as IBD, which is
a significant cancer risk factor. Indeed, it has been found that
pxr-null mutant mice showed increased expression of NF-kB target
genes and marked intestinal inflammation (Zhou et al, 2006)
reminiscent of that seen in humans with inflammatory bowel
diseases such as the celiac disease (Kagnoff, 2005). Consistent with
this PXR-NF-kB mutual repressive cross talk, it has been observed
that activation of PXR by the agonist pregnenolone-16a-carboni-
trile (PCN) significantly reduced dextran sulphate sodium-induced
IBD in mouse model (Shah et al, 2007). The protective effects of
PCN were not seen in pxr-null mice indicating the pivotal role of
PXR in controlling the chemical-induced inflammation in the
intestine. It has also been reported that mouse expressing
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reduced damage to the intestinal epithelium from carcinogen or
toxic chemicals (Sonoda et al, 2002).
Recent studies implicated PXR in regulation of cell proliferation.
It was found that PXR-null mice showed impaired hepatocyte
proliferation after partial hepatectomy suggesting that PXR is
required for normal progression of liver regeneration by
modulating hepatocyte proliferation (Dai et al, 2008).
Collectively, emerging evidence shows the involvement of PXR
in regulating carcinogenesis and tumour progression independent
of its known role in detoxification and metabolic activation of
carcinogens. To analyse these recently appreciated roles of PXR
in regulating cancer cell growth, we performed in vitro and
in vivo experiments using cell culture and xenograft tumour
assays. These experiments led to the discovery that PXR is directly
involved in suppression of tumour growth through functional
regulation of cell-cycle progression through induction of p21
WAF1/CIP1
and reduction of E2F1 expression. These observations strongly
suggest that PXR possesses tumour suppressor activity that might be
used for cancer prevention and therapy.
MATERIALS AND METHODS
Human colon cancer samples
A total of 40 cases of human colon cancer and their adjacent
normal colon mucosa tissue specimens were obtained from colon
cancer patients (27 men and 13 women, age from 52 to 74 years)
in the Department of Pathology, First Affiliated Hospital of
Guangzhou Medical College, China, between 2007 and 2008. All
cancers were medium-differentiated adenocarcinoma. The samples
were fixed with 4% buffer neutralised formalin, paraffin-embedded
and cut into 4mm sections. The protocol for the use of human
samples was approved by the institutional review board of the
hospital.
Cell culture, plasmids and antibodies
HT29 and HepG2 cells were cultured in DMEM medium (HyClone,
Logan, UT, USA) with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA, USA) and 1% antibiotics and antimycotics
(Gibco) and maintained at 371Ci n5 %C O 2. The PXR-mediated
luciferase reporter genes were constructed by inserting the
xenobiotic response element module and proximal promoter
sequences from CYP3A4 into the pGL3Basic vector (Promega,
Madison, WI, USA) as described previously (Gu et al, 2006). The
antibodies used in this study were from the following vendors:
PXR (PP-H4417-00; R&D Systems, Minneapolis, MN, USA),
p21
WAF1/CIP1 (M7202; Dako, Denmark), Ki-67 (sc-15402), p53
(sc-6243) and E2F1 (sc-251) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Stable transfection and luciferase assay
HT29 cells were seeded in the 12-well plates at about 70%
confluence and transfected with PXR expression plasmids (named
PXR-HT29) or vector control (Vector-HT29) using Lipofectamine
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
protocol. The transfected cells were then selected by neomycin
(1mgml
 1) for 15 days. PXR expression was verified by western
blot and immunocytochemical staining using antibody against
PXR. For luciferase assay, we treated transfected cells in triplicates
with either PXR ligand rifampicin (10mM) or DMSO as the control
for 48h, then collected and assayed for luciferase activity in a
luminometer using the Reporter Lysis Buffer System (Promega).
PXR was also transfected into HepG2 cells using the same method.
MTT assay
Cell viability and proliferation were determined by 3-(4,5-di-
methylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay.
Briefly, HT29 or HepG2 cells with or without PXR transfection
were seeded in 48-well plates with 0.2ml media per well and were
grown for 14 days under standard cell culture conditions. The
cultured cells were washed with RPMI-1640 without phenol red
and incubated with MTT solution (0.5mgml
 1)a t3 7 1C for 3h to
allow MTT to be metabolised. The medium was removed and
1ml acidic isopropanol was added for dye conversion in each well.
The supernatant was transferred into tubes, centrifuged and
measured at a wavelength of 570nm with background subtra-
ction at 650nm in disposable cuvettes by a spectrophotometer
(Beckman, Brea, CA, USA; DU-600).
Soft agar assay for colony formation assay
The cultured HT29 or HepG2 cells with or without transfected PXR
were mixed with culture medium containing 0.25% agarose and
plated at a density of 2 10
4 per well on the pre-solidified bottom
of 0.5% agarose with the same medium in six-well plates. The
plates were incubated at standard cell culture condition up to 3
weeks. The results were recorded by photography and the colonies
with a diameter above 100mm were determined by ImagJ program
(NIH, Bethesda, MD, USA).
Western blot
The cultured cells were scraped off the plates using cell scraper
and the samples were boiled in 2 SDS sample buffer. The
proteins were separated by 8% SDS–polyacrylamide gel (PAGE).
Proteins on the gel were transferred to nitrocellulose membranes
(Bio-Rad, Hercules, CA, USA) and the membranes were blocked
with 5% bovine serum albumin in Tris-buffered saline with 0.1%
Tween 20 (TBST) (20mM Tris-HCL (pH 7.6), 137mM NaCl,
2.68mM KCl, 0.05% Tween 20), and incubated with appropriate
primary antibodies at 371C for 60min. Blots were washed three
times with TBST, then incubated with a 1:2000 dilution of
immunoaffinity-purified goat anti-rabbit IgG linked to alkaline
phosphatase (AP). Blots were washed three times with TBST and
subsequently developed using the western blot AP substrate
(Promega).
Cell cycle analysis with flow cytometry
Cells transfected with PXR or vector were cultured up to 70%,
treated with DMSO or rifampicin for 24h and collected by
trypsinisation. Cells were fixed in 70% ethanol for 2h, followed
washing with phosphate-buffered saline (PBS) twice and
re-suspended in propidium iodide (20mgml
 1) staining solution
containing 1mgml
 1 RNase in 10mM PBS (pH 7.4) for 30min at
room temperature. Flow cytometry analysis was performed
immediately in an FACSCalibur flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA) with an excitation at
488nm and an emission at 620nm. Triplicate experiments were
always performed.
Immunocytochemistry
To confirm the expression of transfected PXR in situ, immunocyto-
chemical staining with PXR antibody was performed in cultured cells.
PXR-HT29 and Vector-HT29 cells were seeded in the 8-well chamber
slides, cultured for 2 days and fixed with 4% neutral buffered
formaldehyde solution for 20min. Microwave-heated antigen retrieval
was performed in 0.01moll
 1 citric acid buffer (pH 6.0) for 15min.
Cells were treated with 0.1% Triton X-100 for 10min, then blocked
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swith normal donkey serum for 30min and then incubated with PXR
m o u s em o n o c l o n a la n t i b o d y( R & DS y s t e m s )a td i l u t i o n1 : 1 0 0
o v e r n i g h ta t4 1C. After washing with PBS containing 0.1% Tween
20 (PBST), the biotinylated secondary antibody and the streptavidin–
biotin complex (Invitrogen) were applied, each for 30min at room
temperature with an interval PBST washing. 3,30-Diaminobenzidine
(Sigma, St Louis, MO, USA) solution (0.4mgml
 1, with 0.003%
hydrogen peroxide) was used as a substrate for developing colour.
The slides were then counterstained with haematoxylin, dehydrated
and mounted with coverslips. The results were visualised on an
Olympus (AH-3; Olympus, Tokyo, Japan) microscope equipped with
a SPOT INSIGHT COLOR digital camera, and images were obtained
using SPOT DIGITAL CAMERA SYSTEMS software (Diagnostic
Instruments Inc., Sterling Heights, MI, USA).
In vivo tumourigenesis assay
Female BALB/c nude mice (24, aged 6–8 weeks) were divided into
four groups (Workman et al, 1998). A total of 7.5 10
6 HT29 cells
with transfected PXR gene or vector were subcutaneously injected
into the nude mice at right flank. All animals received either corn
oil or rifampicin (100mg/kg per day intraperitoneal) treatment
from day 6 to day 16. The tumour size was measured by a vernier
caliper every 2 days from day 6 to day 16 after cell implantation.
The volume was calculated by a formula: V¼0.5a b
2, where a is
the long diameter and b the short diameter. The animals were
killed on day 16. The tumour was removed from the body, weighed
and cut into two pieces. One piece was fixed with 4% neutral
buffered formaldehyde solution and another one was frozen in
liquid nitrogen for further assays.
Immunohistochemistry
Immunohistochemical stainingw a sp e r f o r m e di nH T 2 9t u m o u r s
from nude mice and human colon cancer samples. Paraffin-
embedded sections (4mm thick) were deparaffinised, re-hydrated
a n dm i c r o w a v e - h e a t e df o r1 5 m i ni n0 . 0 1 m o l l
 1 citric acid buffer
(pH 6.0) for antigen retrieval. Then, 3% hydrogen peroxide was
applied to block endogenous peroxidase activity. After 15min of
blocking with normal serum (Invitrogen), we applied the primary
antibody or corresponding control isotype IgG and incubated
o v e r n i g h ta t4 1C. Slides were washed thrice with PBS, each for
5min. Slides were incubated with the biotinylated secondary antibody
and the streptavidin–biotin complex, each for 30min and washed
three times at room temperature. After rinsing with PBS, the slides
were immersed for 10min in 3,30-diaminobenzidine (Sigma) solution
(0.4mgml
 1, with 0.003% hydrogen peroxide), monitored under
microscope and stop the reaction with distilled water, counterstained
with haematoxylin, dehydrated, and coverslipped. The following
primary antibodies were applied: PXR (PP-H4417-00; R&D Systems),
p21
WAF1/CIP1 (M7202; Dako) and Rb (OP66; Calbiochem, Gibbstown,
NJ, USA); Ki-67 (sc-15402), p53 (sc-6243) and E2F1 (sc-251) were
purchased from Santa Cruz Biotechnology. The working concentra-
tion of all primary antibodies was 2mgml
 1.
Immunofluorescence double staining
Paraffin-embedded sections were deparaffinised, re-hydrated and
microwave-heated for 15min in 0.01moll
 1 citric buffer (pH 6.0)
for antigen retrieval. After blocking with 10% donkey serum
(Jackson ImmunoResearch, West Grove, PA, USA) for 30min, the
primary antibody solution containing mouse anti-PXR antibody
(1:100) and rabbit anti-Ki-67 antibody (1:100) or the solution of
corresponding isotype control IgGs at the same concentration with
primary antibody was applied and incubated overnight at 41C.
Sections were washed with PBS for three times, each for 5min. The
secondary antibody solution containing donkey anti-mouse
antibody conjugated with orange-red fluorescent AF568 and
donkey anti-rabbit antibody conjugated with green fluorescent
AF488 (both from Invitrogen and at dilution of 1:1000) was
applied in dark for 30min. Slides were washed three times with
PBS and mounted with aquatic medium contained DAPI.
TUNEL assay
Terminal deoxyribonucleotide transferase-mediated nick-end
labelling (TUNEL) staining was performed using the In situ Cell
Death Detection kit (Roche Applied Science, Indianapolis, IN,
USA) following the instructions of the manufacturer. Briefly,
4-mm-thick formalin-fixed, paraffin-embedded tissue sections were
deparaffinised and re-hydrated. Endogenous peroxidase activity
was quenched by hydrogen peroxide and tissue protein was
hydrolysed with proteinase K. Positive control are sections treated
with DNase I 1000Uml
 1. Negative control sections are incubated
with label solution (without terminal deoxynucleotidyl transferase
enzyme). All other sections were incubated with TUNEL reaction
mixture (fluorescein-labelled nucleotides) at 371C for 1h in
a humid chamber, incubated with converter-POD solution
(anti-fluorescein antibody conjugated with POD) for 30min at
371C, treated with DAB and counterstained with haematoxylin.
Quantitative measurement
The quantitative analysis of immunohistochemical staining with
nuclear positive was performed by PhotoShop and ImageJ (NIH)
programs and 10–15 photos per sample were taken randomly. We
chose the positive staining by PhotoShop Color Range and saved it
as the criterion for all samples. The chosen area was filled with
white colour and the rest with black colour. Then the function of
Analyze Particle in ImageJ Program was applied to count the
number of positive nuclei.
Statistics
All data were analysed by comparing means with one-way ANOVA
method using SPSS (Chicago, IL, USA; version 11.5.0). An additional
Duncan’s post hoc test was followed for the results of luciferase
activity and cell-cycle assay. Data are shown as mean±s.e.m. and
Po0.05 denotes statistically significant difference.
RESULTS
Loss of PXR in human colon cancers and restoration of
PXR by stable transfection of PXR gene in HT29 cells
To analyse the role of PXR in colon carcinogenesis, we surveyed
the PXR gene expression in 30 human colon cancer samples with
adjacent normal colon mucosa as control using immunohisto-
chemistry. The normal epithelial cells of 73.3% (22 out of 30) cases
showed weak to medium PXR expression (Figure 1A) but 80% (24
out of 30) of cancer samples showed negative staining (Figure 1B).
In an earlier study, we noticed that in many cell lines derived
from GI tract, such as HepG2 and HT29 cells, expression of PXR is
lost (Xie et al, 2009). To investigate the effects of PXR on tumour
cell growth, we restored PXR expression through transfection of
human PXR into the HT29 colon cancer cell line. The PXR
expression levels in the transfected HT29 cells were confirmed by
immunocytochemical staining (Figure 1D) and western blot
(Figure 1E). The gene regulatory function of this ectopically
expressed PXR was tested with co-transfection of a PXR-mediated
luciferase reporter gene. Luciferase activity was induced (4.5-fold,
Po0.05) after transfection with PXR, and the PXR ligand
rifampicin markedly increased the luciferase response (15.7-fold,
Figure 1F), suggesting that the transfected PXR restored its normal
transcriptional properties.
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and HepG2 cells
Upon expression of PXR through stable transfection of HT29
and HepG2, we noticed that PXR expression inhibited cell
growth. To further investigate the PXR-regulated cell proliferation,
we performed MTT assays to quantify the difference of cell
growth and proliferation in colon cancer cell line HT29 and
liver cancer cell line HepG2. The results showed that the
cell proliferation was inhibited significantly (68.7% inhibition,
Po0.01) in PXR-HT29 group compared with Vector-HT29
group and 53.6% (Po0.01) reduction in PXR-HepG2 cells
compared with Vector-HepG2 cells at day 8 after cells seeding
(Figure 2A).
To further characterise the growth-inhibiting property of PXR,
we performed anchorage-independent growth assays in soft agar
(Figure 2B). The presence of PXR significantly reduced colony
formation in HT29 cells (39.3±2.7 vs 7.0±1.5 colonies per well,
Po0.01) and HepG2 (33.7±3.8 vs 5.7±1.5, Po0.01) 3 weeks after
cell seeding on the plates (Figure 2C).
PXR inhibits xenograft tumour growth
To further analyse the tumour inhibitory effects of PXR, we
implanted HT29 cells transfected with PXR or vector into nude
mice. The tumour volumes were measured every other day. The
tumour volume calculated by both long diameter and short
diameter in PXR-HT29 group was significantly smaller than that in
Vector-HT29 group (441±78 vs 173±18mm
3, Po0.05) at day 16.
The growth rate of the tumour xenografts was significantly lower
than the vector control group (Figure 3A). The tumours were
removed from mice on the termination of the experiments and
showed a readily apparent difference in size between Vector-HT29
group and PXR-HT29 group (Figure 3B). The final tumour weight
of the xenografts was significantly different between two groups
(310±6.2 vs 120±6mg, Po0.01; Figure 3C).
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Figure 1 PXR expression is lost in human colon cancer and restored in HT29 cells by stable transfection. The normal human colon mucosae express PXR
in the cytoplasm (indicated by arrow), which was lost or greatly diminished in colon cancer cells as determined by immunohistochemistry (A and B). The
expression of PXR was restored by stable transfection of PXR gene (compare parental HT29 cells, C and HT29 cells stably transfected with PXR, D) and
expression was confirmed by western blot analysis (E, lanes 1, 2, 3 are vector-HT29 and lanes 4, 5, 6 are PXR-HT29) and transcriptional activity of PXR was
confirmed by luciferase reporter gene assay in HT29 cells co-transfected with PXR and PXR-driven luciferase reporter gene. The luciferase reporter gene
was significantly induced (Po0.01) in PXR ligand rifampicin-treated group (*indicated) compared with DMSO vehicle control (F).
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staining but does not induce apoptosis in HT29 xenograft
tumours
To determine the mechanism by which PXR inhibited the tumour
growth in nude mice, we measured cell proliferation and apoptosis
by immunohistochemistry, immunofluorescence double staining
and TUNEL assay in the excised xenografts. Robust nuclear
expression of PXR protein was retained in most of the tumour cells
(450%) from the PXR-HT29 xenografts (Figure 4). Cells positive
for the proliferation marker Ki-67 were noticeably reduced in
PXR-HT29 xenografts (Figure 4A). The number of Ki-67-positive
cells was quantified using the ImageJ program, and significantly
low number of Ki-67-positive cells were found in the PXR-HT29
xenografts (50.13±4.96 vs 30.47±5.19, Po0.01; Figure 4B). To
determine the level of apoptosis in the xenograft, we performed
TUNEL assay. There were no significant differences in the PXR-
HT29 and vector control xenograft (5.79±0.57 vs 5.03±0.53 cells
per field, P40.05; Figure 4A and C), suggesting that the reduction
of tumour sizes was not caused by apoptosis. Interestingly, results
of PXR and Ki-67 immunofluorescence double staining indicate
that the expression levels of PXR and Ki-67 are mutually exclusive
(Figure 4A, bottom panel), strongly suggesting the anti-prolifera-
tive function of PXR.
PXR suppresses cell proliferation by induction of G0/G1
cell-cycle arrest
To determine the cell phase of HT29 being regulated by PXR, we
stained the cells with propidium iodide and analysed by flow
cytometry. The results indicated that the percentage of cells at
G0/G1 phase was significantly higher in PXR-HT29 cells than in
Vector-HT29 cells (67.2±1.9 vs 40.5±1.4%, Po0.01) and the
percentage of cell population at S phase and G2/M phase was
significantly lower in PXR-HT29 cells than in Vector-HT29 cells
(25.2±0.6 vs 43.6±1.2%, Po0.01 and 7.6±0.6 vs 15±2.5%,
Po0.01, respectively), suggesting that induction of G0/G1 cell-cycle
arrest was the primary mechanism by which PXR inhibits
proliferation in HT29 cells (Figure 5). This experiment was
conducted with control and PXR ligand, and cell-cycle suppressive
effects of PXR seem to be ligand independent.
PXR upregulates p21
WAF1/CIP1 expression and inhibits E2F1
expression
p21
WAF1/CIP1 has been found to have a crucial regulatory role in
cell-cycle control by inhibiting CDK4 and preserving the Rb/E2F
complex. Immunohistochemistry staining of xenograft tumours
showed that p21
WAF1/CIP1 expression was remarkably higher in
PXR-HT29 tumours than in Vector-HT29 tumours (Figure 6A and
C), but p53 expression appeared to be the same in the two groups
most likely due to p53 mutation in HT29 cells.
E2F/Rb signal transduction is one of the most important
pathways for cell growth progression in the G1 phase of the cell
cycle. When Rb is phosphorylated by cyclin D–CDK4 complexes
E2F is released from the Rb–E2F complex and promotes cell-cycle
progression. From immunohistochemistry staining, we found E2F1
expression was significantly lower in PXR-HT29 tumours com-
pared with Vector-HT29 tumours (Figure 6A and D). Western blot
analysis further confirmed the differential expression of E2F1 in
the xenograft tumours from both groups (Figure 6B). The most
well-known regulator of p21
WAF1/CIP1, p53, is mutated in HT29 cancer
cell line and the amount of the transcriptionally inactive p53 found in
these cells accumulates in the nucleus. PXR expression did not change
p53 expression in these xenograft tumours.
DISCUSSION
Although PXR has been recognised for its involvement in
xenobiotic/drug metabolism through its role as a ligand-dependent
transcription factor in the regulation of detoxifying enzymes
such as CYP3A4, UGT1A1, GST and transporters (Handschin
and Meyer, 2003), recent research reveals unexpected novel
physiological functions, many of which seem to be rooted at its
fundamental role as the sensor and effector guarding the organism
against mutagenic insults from xenobiotics and endobiotics.
Interestingly, in addition to reducing mutagenic DNA damages,
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Figure 2 PXR restoration inhibited cancer cell proliferation and colony formation in anchorage-independent culture. MTT assays showed that the viable
cells were inhibited significantly in PXR-HT29 and PXR-HepG2 cells comparing to vector control cells (*, P’so0.01) at day 14 time point after cells seeding
on the plates (A). For soft agar assay, the results were recorded by microphotography and the colonies with a diameter above 100mm were counted by
ImageJ program (B), and the number of colonies was markedly decreased in both PXR-HT29 and PXR-HepG2 cells compared with vector control cells.
PXR stands for PXR-transfected HT29 or HepG2. In (C), *, P’so0.01.
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protect cells from unregulated proliferation, which is a critical step
for tumourigenesis. In earlier studies, we observed that many
cancer cells lines derived from GI tract, such as HepG2, HT29 and
HCT116, showed loss of PXR expression (Xie et al, 2009; data not
shown). Upon ectopic expression of PXR through transfection, the
PXR function could be restored and cells showed significant
reduced proliferation, suggesting its role in controlling tumour cell
proliferation. It has been reported that certain polymorphisms of
PXR were identified to be strongly associated with the suscept-
ibility to IBD (Dring et al, 2006), which is a significant risk factor
for colon cancer. In patients with IBD, decreased expressions of
PXR and its target genes have been observed (Langmann et al,
2004; Martinez et al, 2007). On the basis of collective evidence, we
hypothesised that PXR has tumour suppressor activity and
investigated the effects of PXR expression in PXR-negative colon
cancer cells in vitro and in vivo (Workman et al, 1998).
In this study, we have shown that transfected PXR significantly
suppressed HT29 cancer cell proliferation, anchorage-independent
growth and tumourigenicity in xenograft assays. In tumour
xenograft model, the PXR expression was retained in the
HT29 cells 2 weeks after xenograft transplantation into nude mice
and the tumour size was markedly suppressed by PXR. Interest-
ingly, results of immunofluorescence double staining suggest
that PXR and Ki-67 expressions are mutually exclusive (Figure 4),
suggesting at cellular level the presence of PXR is inhibitory
for the colon cancer cell growth. At organ/tissue levels however,
PXR may regulate the growth of cell/tissues through different
mechanisms. Wan and colleagues reported the mouse lacking
PXR showed decreased liver regeneration after partial hepatectomy
and the PXR-regulated lipid homoeostasis, which fuels the
liver regeneration, may have a role in the suppressed liver growth
(Dai et al, 2008). Verma et al (2009) reported that PXR
activation induced apoptosis in breast cancer cell line and PXR
is anti-proliferative and the effect is mechanistically dependant on
the local production of NO and NO-dependent upregulation
of p53. As the HT29 cells have mutated p53, the mechanism of
PXR-regulated inhibitory effects on HT29 growth may differ
from the NO-dependent upregulation of p53 reported. Interest-
ingly, Gupta et al (2008) reported that in ovarian cancer
cell lines certain PXR target genes such as CYP3A4 and UGT1A1
were inducible by rifampicin and the ligand promoted the
proliferation of the ovarian cancer cell line in culture and
xenograft model. The underlying mechanisms for these differences
in the roles of PXR in regulating proliferation and apoptosis of
colon, breast and ovarian cancer cells are not clear and warrant
further investigation. The important questions that await further
investigation are what is the physiological level of PXR expression
in various tissues, what are the factors that influence its
expression/functions, and ultimately, what is the mechanism by
which PXR regulates cell cycle.
To investigate the role of PXR in regulation of cell cycle, we first
performed flow cytometry analysis of the effects of PXR on the
cell cycles and our study results showed that PXR caused G0/G1
cell-cycle arrest. Cyclin-dependent kinase (CDK) inhibitors
p21Cip1/Waf are important as the negative regulator of cell-
cycle progression (Gartel and Radhakrishnan, 2005). Normally
p21
WAF1/CIP1 has an inhibitory role regarding cyclin D–CDK4
complex phosphorylation of Rb and is regulated principally by the
tumour suppressor p53. The p53 gene is mutated in HT29 cell line
and is transcriptionally inactive. Our study results showed
that p21
WAF1/CIP1 expression is almost completely absent in
Vector-HT29 cancer cells but highly expressed in PXR-HT29 cells
determined by immunohistochemistry analysis and western
blot analysis (Figure 6A–C). Interestingly, the expression of
E2F1 was negatively correlated with the p21 expression, suggesting
its expression is downregulated by the presence of PXR. It has been
shown that control of the p53–p21
CIP1 axis by E2F family genes is
essential for G1/S progression and cellular transformation (Sharma
et al, 2006). It is possible that the negative interaction between p21
and E2F1 was lost in certain colon cancer cells and restored on PXR
expression, the mechanism of reduction of E2F1 remains to be
investigated. Comparison of the apoptotic cells in the xenograft
tumour tissues by TUNNEL staining shows no significant difference
between the PXR-HT29 and parental HT29 tumours. However, flow
cytometry analysis with the Annexin V antibody staining in cell
culture showed slight increases in apoptosis in PXR-HT29 cells (data
not shown). Therefore, both cell-cycle regulation and apoptosis may
have a role in PXR-regulated suppression of colon cancer growth,
however, overall our study results shows that the regulation of cell-
cycle appears to be a primary mechanism by which PXR inhibits
tumour growth.
In conclusion, our study results suggest that PXR has a novel
anti-proliferative function in vitro and in vivo, beyond its known
role in control of metabolism. This function appears to be exerted at
T
u
m
o
u
r
 
s
i
z
e
 
(
m
m
3
)
400
300
200
100
0
600
500
Vector-HT29
PXR-HT29
Vector-HT29
PXR-HT29
68 10 12 14 16
Post-injection (day)
T
u
m
o
u
r
 
w
e
i
g
h
t
 
(
g
)
0.6
0.4
0.2
0
Vector-HT29 PXR-HT29
*
*
Figure 3 PXR inhibits growth of tumour xenograft in nude mice.
PXR-HT29 or Vector-HT29 cells were injected subcutaneously into nude
mice at concentration of 7.5 10
6 per injection. The tumour size was
measured every 2 days. The tumour growth of PXR-HT29 group was
significantly inhibited in the xenograft carrying PXR than that of control
group at 16 days after initial injection (A,* Po0.01, n¼12). The tumours
were then removed from the nude mice and imaged (B) and the final
weights were significantly different between PXR-HT29 and Vector-HT29
groups (C,* Po0.01, n¼12).
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Figure 4 PXR inhibits cell proliferation. The xenograft tumours removed from nude mice were analysed by immunohistochemistry for expression of PXR
and Ki-67. TUNEL assay was also performed to determine the level of apoptosis. Ki-67-positive cells were markedly decreased in PXR-HT29 xenograft
tumour tissues in comparison with the control (A and B). There were no significant differences in apoptotic levels between PXR-HT29 and control as
determined by TUNEL assay (A and C). Immunofluorescence double staining of PXR-HT29 xenograft tumour tissues showed a mutually exclusive
distributing pattern of PXR and Ki-67 (A, bottom) further confirming the anti-proliferative effect of PXR. *Po0.01.
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Figure 5 PXR suppresses cell proliferation by causing G0/G1 arrest in cell cycle. PXR-HT29 and Vector-HT29 cells were stained with propidium iodide
and analysed by flow cytometry. The percentage of cell population in G0/G1 phase was significantly higher in PXR-HT29 group (lower panel) than in
Vector-HT29 group (67.2±1.9 vs 40.5±1.4%, Po0.01) suggesting G0/G1 arrest.
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WAF1/CIP1 control of the E2F/Rb pathway
in HT29 cells. These novel results suggest potential applications
for new therapies for colon cancer treatment based on modulation
of PXR function.
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